Economic Overview
Macroeconomic and Policy Context
The global economy remained resilient in CY2025 despite geopolitical tensions, trade uncertainties and inflationary pressures. Global GDP expanded by 3.4%,? while emerging economies continued to outpace advanced economies. However, evolving trade dynamics and supply chain disruptions continued to create uncertainty across industries.
India sustained strong growth momentum in FY2025-26, with GDP expanding by 7.6%,? supported by robust domestic demand, infrastructure investments and manufacturing growth. Continued government focus on capital expenditure and industrial development strengthened the countrys long-term growth outlook.
Against this backdrop, the pharmaceutical industry continued to benefit from structural demand drivers, including ageing populations, rising prevalence of chronic diseases and improving healthcare access. Looking ahead, global GDP growth is projected at 3.1% in CY2026 and 3.2% in CY2027, while continued investments in healthcare infrastructure, pharmaceutical supply security and affordable medicines are expected to support the industrys long-term growth.
Granules continues to strengthen its focus on operational excellence, regulatory compliance, innovation-led growth and supply chain resilience, positioning the Company to capture emerging opportunities while delivering sustainable value to stakeholders.
Industry Overview
Global Pharmaceutical Market?
Global Medical Spending and Growth, Excluding COVID-19 Vaccines and Therapeutics, Constant (20202030)
(in USD Billion)
(Chart data points: 2020: 1,256; U.S.: 374; Other high GDP larger growth: 144; High GDP smaller growth: 23; Pharmerging: 118; Rest of world: 21; 2025: 1,936; U.S.: 389; Other high GDP larger growth: 155; High GDP smaller growth: 25; Pharmerging: 121; Rest of world: 26; 2030: 2,651)
Source: IQVIA Global Medicine Use Trends 2026
Global demand for pharmaceuticals continues to rise, supported by expanding healthcare access, ageing populations and the increasing prevalence of chronic diseases. According to IQVIA, global medicine consumption is projected to approach 4 trillion defined daily doses (DDDs) by CY 2030, while global medicine spending is expected to exceed USD 2.6 trillion, growing at an estimated 58% annually. Developed markets are expected to remain the primary drivers of value growth through continued adoption of innovative therapies, particularly across oncology, immunology, diabetes and obesity, while emerging markets are projected to contribute significantly to volume growth as healthcare access continues to improve.
Over the coming years, the pharmaceutical industry is expected to be shaped by patent expiries, increasing adoption of biosimilars, expanding specialty medicines and continued investment in innovation, alongside a growing focus on affordability and healthcare accessibility. At the same time, pharmaceutical companies are strengthening resilient supply chains, integrated manufacturing capabilities and geographically diversified operations to support faster commercialisation and reliable product availability across regulated markets.
These evolving industry dynamics are creating significant opportunities across differentiated generics, specialty therapies, peptide technologies and advanced pharmaceutical manufacturing. The following table highlights how these global pharmaceutical trends align with Granules strategic growth engines and support its long-term growth strategy.
Alignment of Global Pharmaceutical Trends with Granules Growth Engines
| Global Growth Driver | Industry Outlook | Alignment with Granules Growth Engine |
| Growing demand for complex generics | Patent expiries and increasing focus on affordable healthcare are expanding opportunities for differentiated and high-barrier generic medicines across regulated markets. | Complex Generics Scale-up Expansion of controlled substances, complex formulations and differentiated generic portfolio. |
| Rapid growth in peptide therapeutics | Peptide-based therapies, particularly GLP-1 medicines for diabetes and obesity, are among the fastest-growing pharmaceutical segments globally. | Peptide Platform Expansion of peptide capabilities through Senn Chemicals and Ascelis Peptides. |
| Increasing focus on specialty therapies | Oncology, immunology and other specialty medicines are expected to remain the largest contributors to global medicine spending growth through 2030. | Innovation Platforms & Oncology Pipeline Strengthening R&D across CNS, oncology, peptides and other high-value therapeutic areas. |
| Integrated pharmaceutical manufacturing | Pharmaceutical companies increasingly prefer integrated development and manufacturing partners to improve quality, speed-to-market and supply chain resilience. | Capacity Expansion Leveraging vertically integrated operations and expanding manufacturing infrastructure, including the Genome Valley facility. |
| Supply chain diversification | Global pharmaceutical companies continue to diversify sourcing and manufacturing across regulated markets to improve resilience and business continuity. | Geographic Diversification Expanding presence across Europe and other regulated markets alongside North America. |
| Rising pharmaceutical innovation | Continued investments in advanced drug development and differentiated technologies are accelerating the shift towards higher-value pharmaceutical products. | Innovation Platforms Continued investment in complex generics, peptide technologies and differentiated product development. |
?https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-medicine-use-trends-2026
United States4
The United States remains the largest and most innovation-driven pharmaceutical market globally. Growth in CY 2025 has been supported by increased uptake of specialty and high-value therapies, particularly in oncology and immunology.
Key Growth Drivers
- Strong adoption of innovative and specialty medicines
- Rising use of high-cost, high-value therapies
- Continued leadership in drug innovation and launches
- Increasing patient access to advanced treatments
Outlook
The U.S. pharmaceutical market is expected to grow at a healthy rate through CY 2029, with growth driven primarily by innovation and therapy mix. However, pricing pressures and regulatory changes may moderate overall expansion.
Europe5
Europe remains a mature pharmaceutical market with high per capita medicine usage, significantly above most other regions. Growth is relatively moderate, reflecting market maturity and pricing controls.
4https://www.iqvia.com/-/media/iqvia/pdfs/events/presentation_global-meds-webinar_public.pdf
5https://www.iqvia.com/-/media/iqvia/pdfs/events/presentation_global-meds-webinar_public.pdf
Spending and growth drivers in France, Germany, Italy, Spain and UK (20182028)
(in USD Billion)
(Chart data points: 2019 spending: 168; New brands: 37; LOE: -31; Existing brands: 32; Generics: 12; Others: 3; 2024 spending: 242; Forecast -> New brands: 45; LOE: -26; Existing brands: 52; Generics: 10; Others: 3; 2029 spending: 327)
Source: IQVIA The Global Use of Medicines 2025: Outlook to 2029
Key Growth Drivers
- Strong demand for innovative and specialty therapies
- Increased use of biosimilars and cost-efficient treatments
- Aging population and rising chronic disease burden
- Expansion of access to new medicines across countries
Outlook
Growth in Europe is expected to remain steady but moderate, with limited volume expansion. The Pharmaceutical spending in Europe is projected to rise by $85 billion by CY 2029, primarily driven by both newly launched and established branded medicines.
Japan6
Japan continues to be a large but slow-growing pharmaceutical market, characterised by high healthcare standards and widespread access to medicines. Growth remains below the global average.
Key Growth Drivers
- Rapidly aging population, increasing healthcare demand
- Continued uptake of innovative therapies
- Focus on treatment of chronic and age-related diseases
Outlook
Japan is expected to witness low growth in both volume and spending through CY 2029. While access to innovative drugs is improving, cost containment measures and pricing controls will continue to limit market expansion.
India and Pharmerging Markets7
Pharmerging markets, defined as countries with GDP per capita below USD 50,000 and pharmaceutical growth exceeding USD 2 billion through CY 2030 continues to be key drivers of global medicine demand. While overall global spending growth is expected to moderate in the coming years, these markets will play an increasingly important role in sustaining expansion.
Pharmerging Markets Growth (2026-2030)
(in USD Billion)
(Chart data points by region: Brazil 18, India 17, Russia 13, T?rkiye 13, China 6, Mexico 6, Egypt 4, Romania 4, Thailand 3, Pakistan 3, Vietnam 3, Argentina 2, Indonesia 2, Greece 2, Colombia 2)
Source: IQVIA Global Medicine Use Trends 2026
6https://www.iqvia.com/-/media/iqvia/pdfs/events/presentation_global-meds-webinar_public.pdf
7https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-medicine-use-trends-2026
Key Growth Drivers
- Rising income levels and healthcare access
- Strong growth in medicine consumption and affordability-driven demand
- Increasing burden of chronic and lifestyle diseases
- Expansion of healthcare infrastructure and insurance coverage
Outlook
Pharmerging markets are expected to grow by USD 121 billion through CY 2030, slightly higher than the growth recorded over the past five years. Notably, the top eight pharmerging countries will contribute around 83% of this growth, highlighting concentrated expansion in key economies.
Overall, these markets are expected to remain the fastest-growing segment of the global pharmaceutical industry, driven by both rising volumes and improving access to therapies.
Company Overview
Granules India Limited is a vertically integrated pharmaceutical Company with capabilities spanning the entire value chain, including Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), Finished Dosages (FDs) and peptide/CDMO operations. The Companys integrated business model, supported by scale, cost efficiency, backward integration and strong regulatory capabilities, enables it to serve more than 300 customers across over 80 countries.
North America continued to remain the Companys largest market during FY 2025-26, while Europe emerged as a strong growth contributor. Finished dosages remained the core business, contributing 74% of total revenues, supported by a growing portfolio of complex generics and value-added formulations. Granules is steadily transitioning towards a more differentiated and value-driven business model with increasing focus on complex generics, controlled substances, oncology and peptide therapeutics.
The Companys manufacturing footprint across India and the US, supported by global R&D capabilities, regulatory expertise and an expanding product pipeline, positions it to strengthen its presence across regulated markets and support long-term sustainable growth.
Strategic Priorities
Granules is advancing its transformation into a quality-driven, innovation-led and value-focused global pharmaceutical company. The Companys strategy is centred on strengthening operational excellence, expanding differentiated product offerings and building new growth platforms that support long-term sustainable growth and improved earnings quality.
I. Strengthening Quality, Compliance and Manufacturing Scale
Granules continues to strengthen its operational backbone through investments in quality systems, regulatory compliance, digital infrastructure and manufacturing scale across its global network.
Key strategic priorities include:
- Strengthening quality and compliance frameworks across manufacturing facilities while advancing remediation initiatives and regulatory engagements.
- Enhancing operational effectiveness through digital quality infrastructure, including electronic logbooks, calibration management systems, document control and MES implementation.
- Scaling formulation manufacturing through the Genome Valley greenfield facility, which adds approximately 10 billion doses of additional capacity to support future product launches and regulated market demand.
- Building a resilient multi-site global supply chain and leveraging vertical integration to enhance supply security, operational flexibility and cost competitiveness.
II. Portfolio Transformation: From Integrated Generics to Complex Generics
Granules is progressively transforming its portfolio from a volume-driven integrated generics model towards a more differentiated and value-driven complex Generics business. During FY 2025-26, Complex Generics contributed 43% of the Finished Dosage portfolio, reflecting the Companys strategic shift towards higher-value products with stronger entry barriers.
The Companys R&D and portfolio expansion efforts are focused on:
- Expanding the pipeline of complex generics, including controlled substances, CNS/ADHD therapies, oncology products and advanced formulation technologies.
- Advancing early-to-market opportunities, including Day-1 launches in regulated markets, including First-to-file applications with potential 180-day exclusivity.
- Developing differentiated dosage forms, MUPS technologies and high-barrier formulations with limited competition.
- Strengthening the global R&D ecosystem supported by a team of over 400 scientists and an expanding regulatory pipeline across APIs and formulations.
- Intensifying BD/IL activities to access complex dosage from and/or delivery system based products for global markets.
III. Building New Growth Platforms: Peptides and CDMO
Granules is building a differentiated growth platform in peptides and Contract Development and Manufacturing (CDMO) through Ascelis Peptides, leveraging the scientific expertise and customer relationships of Senn Chemicals AG in Switzerland.
Key strategic priorities include:
- Developing an integrated global peptide CDMO platform combining Swiss innovation capabilities with scalable development and manufacturing infrastructure in India.
- Strengthening engagement with innovator pharmaceutical, biotechnology and specialty peptide customers across regulated markets.
- Expanding peptide research, development and manufacturing capabilities through the operational peptide Centre of Excellence at IIT Hyderabad and planned peptide intermediates and API capacity expansion in India.
- Building a long-term pipeline of peptide and specialty molecule projects to support the Companys next phase of growth.
Business Overview and Operational Performance
Granules India Limited operates a vertically integrated pharmaceutical business spanning Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), Finished Dosages (FDs) and peptide/CDMO operations. The Company continues to strengthen its formulations-led business model while leveraging backward integration, manufacturing scale and operational efficiency to enhance supply reliability and cost competitiveness. During FY 2025-26, Finished Dosages remained the largest revenue contributor, accounting for 74% of total revenues, followed by APIs at 13%, PFIs at 10% and the emerging peptide/CDMO business at 3%.
Operational performance strengthened during the year, supported by robust growth in finished dosage sales across regulated markets, particularly North America and Europe. Growth was driven by increased demand from existing customers, new product launches and the continued expansion of the Complex Generics portfolio, including controlled substances and ADHD products in the US market. Europe also emerged as a strong growth contributor during the year, reflecting the Companys expanding international presence and diversified revenue base.
Granules continued to strengthen its manufacturing and supply chain capabilities through capacity expansion at the Genome Valley formulation facility, enhancing supply flexibility and supporting future launches in regulated markets. The Company also continued investing in differentiated growth platforms, including complex generics, oncology products, peptide therapeutics and CDMO capabilities under its Ascelis initiative, supporting its transition towards a more value-driven and innovation-focused portfolio.
Financial and Segment Performance
Granules India delivered a strong financial and operational performance in FY 2025-26, supported by robust growth in Finished Dosages, improving product mix and increasing contribution from Complex Generics and peptide/CDMO operations. Consolidated revenue increased by 20% year-on-year to Rs53,656 million, while EBITDA grew by 25% to Rs11,851 million, with EBITDA margins improving to 22.1%. Profit after tax increased by 19% to Rs5,950 million despite continued investments in R&D, compliance and future growth platforms. Gross margins improved significantly to 65.0%, reflecting favourable portfolio transformation and operational efficiencies.
Finished Dosages (FD)
The FD segment remained the primary revenue contributor, accounting for 74% of total revenues in FY 2025-26. Segment revenue increased by 16% year-on-year to Rs39,893 million, driven by strong demand across North America and Europe, new product launches and increasing contribution from Complex Generics. Growth was supported by products in the CNS/ADHD portfolio, controlled substances and value-added formulations in regulated markets.
Granules continued to strengthen its formulations-led strategy through capacity expansion at the Genome Valley facility and enhanced manufacturing efficiencies across India and the US. The Company also continued transitioning towards a higher-value and differentiated portfolio, with Complex Generics contributing an increasing share of the FD business.
Finished Dosages (FD) Revenue
(Rs in Millions)
| FY 2025-26 | 39,893 |
| FY 2024-25 | 34,336 |
| FY 2023-24 | 29,090 |
Active Pharmaceutical Ingredients (API)
The API segment recorded revenue of Rs6,822 million in FY 2025-26, registering a growth of 10% year-on-year. Growth was supported by new API launches, increasing integration with the formulations business and improved demand for select molecules. APIs continue to play a strategic role in supporting backward integration, supply security and cost competitiveness across the Companys Finished Dosage portfolio.
Granules also continued investments in process optimisation, manufacturing efficiency and integrated product development to strengthen long-term competitiveness in the API business.
Active Pharmaceutical Ingredients (API) Revenue
(Rs in Millions)
| FY 2025-26 | 6,822 |
| FY 2024-25 | 6,185 |
| FY 2023-24 | 9,866 |
Pharmaceutical Formulation Intermediates (PFI)
The PFI segment reported revenue of Rs5,348 million in FY 2025-26, reflecting a growth of 25% year-on-year. Performance improved due to stronger demand, operational efficiencies, and increasing integration with the Companys formulations portfolio. The segment continues to support Granules vertically integrated business model by ensuring supply reliability and manufacturing flexibility across regulated markets.
The Company remains focused on improving product mix, operational productivity and customer engagement within the PFI business while supporting future growth in formulations and complex generics.
Pharmaceutical Formulation Intermediates (PFI) Revenue
(Rs in Millions)
| FY 2025-26> | 5,348 |
| FY 2024-25 | 4,294 |
| FY 2023-24 | 6,108 |
Peptide/CDMO
FY 2025-26 also marked the emergence of peptide/CDMO operations as a new growth platform for Granules following the acquisition of Senn Chemicals AG under the Ascelis initiative. The segment contributed Rs1,593 million in revenue during the year and achieved positive EBITDA in Q4 FY26.
Granules continues to strengthen its peptide development and CDMO capabilities through scientific collaboration between Switzerland and India, while expanding customer engagement across innovator pharmaceutical and biotechnology companies.
Peptide/CDMO Revenue
(Rs in Millions)
| FY 2025-26 | 1,593 |
R&D and Innovation
Granules continued to strengthen research and development as a key driver of long-term growth, portfolio transformation and differentiated product development. During FY 2025-26, the Company invested Rs2,853 Mn towards R&D, representing 5.3% of revenues, with a strong focus on complex generics, CNS/ADHD therapies, oncology, MUPS and other high-barrier formulations. These investments support the Companys strategic transition from a volume-led model towards a value-driven portfolio with increasing contribution from Complex Generics products.
The Companys global R&D network spans facilities in Hyderabad (Genome Valley and Pragathi Nagar), Pune and international research capabilities, supported by a team of scientists working across APIs, formulations and peptide research. During FY 2025-26, Granules filed 6 U.S. ANDAs, 3 EU dossiers, 1 Canadian dossier and 15 filings across various regions, along with 6 U.S. DMFs and 10 additional DMF filings globally. Complex generics continued to account for a meaningful share of filings, reinforcing the Companys focus on sustainable and differentiated growth opportunities, including potential first-to-file launches.
Granules also continued expanding its capabilities in peptides and specialty therapeutics through Ascelis Peptides, integrating the scientific expertise of Senn Chemicals AG with its global development platform. During the year, the peptide CDMO platform achieved positive EBITDA in Q4FY 2025-26, while the Company further strengthened its peptide development ecosystem through its operational peptide Centre of Excellence at IIT Hyderabad and planned expansion of peptide intermediates and API capabilities in India. These initiatives are aligned with the Companys long-term innovation strategy and future growth objectives.
Quality and Compliance
Quality and regulatory compliance remain integral to Granules operations and long-term competitiveness. During the year, the Company continued to strengthen its quality systems and governance frameworks across manufacturing facilities to ensure alignment with global regulatory expectations.
Granules advanced remediation efforts at the Gagillapur Finished Dosage facility, implementing corrective and preventive actions while strengthening contamination controls and enhancing cleaning validation and quality oversight processes with guidance from external experts.
The Company also progressed broader quality enhancement initiatives through revised procedures, strengthened governance mechanisms and capability-building initiatives. Granules remains committed to maintaining robust quality systems and ensuring consistent regulatory compliance across its global operations.
Sustainability and ESG
FY 202526 marked another year of significant progress in Granules sustainability journey, with continued advancement across climate action, responsible sourcing and ESG governance. Sustainability remains integrated into the Companys long-term strategy, supported by measurable environmental improvements, strengthened governance frameworks and industry-leading external recognition.
During the year, Granules achieved a Gold Rating from EcoVadis, placing the Company among the top 5% of participating companies globally (97th percentile). The Company also strengthened its climate leadership by securing an A rating in the 2025 CDP Climate Change assessment, advancing from a B rating in the previous year, while receiving inaugural ratings of B for Water Security and B- for Forests. Granules near-term, long-term and Net Zero (2050 or sooner) emissions reduction targets continue to be validated by the Science Based Targets initiative (SBTi), reaffirming alignment with the 1.5?C pathway. ESG performance was further reinforced through an improved S&P Corporate Sustainability Assessment score of 62/100, an MSCI BB rating, and becoming a signatory to the UN Womens Empowerment Principles.
The Company also strengthened sustainability across its value chain through an enhanced Supplier Sustainability Programme, engaging suppliers representing approximately 80% of procurement spend on climate disclosures, renewable energy adoption and emissions management. Granules was recognised on the CDP Supplier Engagement Assessment 2025 A-List, received Sedex Supplier Plus recognition and won the Sustainability Award at Haleons Winning Together Supplier Summit 2026, reflecting continued progress in responsible sourcing and supply chain sustainability. Operationally, the Company achieved a 32% reduction in Scope 1 and Scope 2 emissions, increased the share of renewable electricity to 69%, recycled 44% of wastewater, and directed 80% of hazardous waste for co-processing, reinforcing its commitment to resource efficiency and low-carbon manufacturing.
Risks and Mitigation
| Risk | Impact | Mitigation Strategy |
| Quality and Regulatory Compliance | Regulatory observations, non-compliance or quality-related incidents may result in operational disruptions, delays in approvals and restrictions on manufacturing or supply. | Continued strengthening of quality systems and compliance frameworks, proactive engagement with regulatory authorities and periodic audits and training programmes. |
| Strategic Growth and Market Diversification | Delays in expansion into new geographies, complex generics, peptides and CDMO opportunities may affect growth and margin expansion. | Focused evaluation of new markets, balanced portfolio diversification and disciplined execution of growth initiatives across integrated and complex molecules. |
| Supply Chain Resilience and Input Availability | Disruptions in raw material availability, logistics networks or supplier concentration may impact production schedules, costs and customer commitments. | Supplier diversification, alternate sourcing arrangements, inventory optimisation and strengthened supplier engagement mechanisms. |
| Information Security and Digital Risks | Cybersecurity incidents, data breaches or system disruptions may impact business continuity and stakeholder confidence. | Strengthening IT and OT security controls, continuous monitoring, cybersecurity assessments and employee awareness programmes. |
| Talent Retention and Leadership Continuity | Attrition of key talent or leadership gaps may impact operational efficiency, execution of strategic initiatives and business continuity. | Structured succession planning, leadership development programmes, employee engagement initiatives and internal capability building. |
| Geopolitical and External Environment Risks | Geopolitical tensions, trade policy changes and macroeconomic volatility may affect logistics, freight costs, supply chains and operating costs. | Continuous monitoring of geopolitical developments, scenario planning, diversified sourcing strategies and adaptive operational planning. |
Outlook
Granules continues to bolster its position in regulated pharmaceutical markets through the convergence of portfolio expansion, operational scale and innovation-led growth. The Finished Dosage segment is expected to remain a crucial growth driver, buoyed by new product launches, expansion of the complex generics portfolio and consistent demand from critical markets such as North America and Europe. The increasing contribution from complex formulations, including the ADHD portfolio in the US, is expected to support revenue growth and margin improvement over the medium term.
The Companys expanded manufacturing capacity, including the Genome Valley formulation facility, provides additional flexibility to scale production and support future product launches. At the same time, Granules continues to strengthen its product pipeline through sustained R&D investments, with multiple filings and approvals across key markets. The focus on integrated and complex generics, supported by strong API capabilities and a growing regulatory pipeline, is expected to create long-term growth opportunities.
Granules is also building new growth platforms in peptides and CDMO through Ascelis platform, leveraging its global scientific capabilities to participate in high-value emerging segments. While the Company remains mindful of regulatory and market challenges, its focus on quality, operational efficiency and innovation positions it well to deliver sustainable growth and create long-term value for stakeholders.
Financial Review
Consolidated Abridged Profit and Loss Statement
(Rs in million)
| Particulars | FY 2025-26 | FY 2024-25 |
| Revenue | 53,656.42 | 44,816.08 |
| EBITDA | 11,851.44 | 9,452.36 |
| PAT | 5,950.21 | 5,015.16 |
| Basic EPS | 24.47 | 20.69 |
Revenue from Operations
Revenue from operations for FY 2025-26 increased to Rs53,656 million from Rs44,816 million in FY 202425, registering a growth of 20% year-on-year. Growth was primarily driven by strong performance in the Finished Dosage segment, supported by increased contribution from Complex Generics, new product launches and sustained demand across North America and Europe. The Company also benefited from improving product mix, higher contribution from value-added formulations and the emergence of the peptide/CDMO business as a new growth platform during the year.
EBITDA
EBITDA for FY 2025-26 stood at Rs11,851 million as compared to Rs9,452 million in FY 202425, reflecting continued improvement in operational performance and margin expansion. EBITDA margins improved to 22.1% during the year, supported by favourable product mix, higher contribution from Complex Generics and improved gross margins. The Company continued to invest in R&D, compliance initiatives and future growth platforms, including peptide/CDMO operations under the Ascelis initiative.
Consolidated Balance Sheet
(Rs in million)
| Particulars | As on March 31, 2026 | As on March 31, 2025 |
| Assets | ||
| Tangible and Intangible Assets | 36,596.60 | 28,666.59 |
| Non-current Assets other than above | 2,926.44 | 2,704.21 |
| Current Assets | 37,676.46 | 31,154.81 |
| Total Assets | 77,199.50 | 62,525.81 |
| Equity and Liabilities | ||
| Share Capital | 247.80 | 242.54 |
| Other equity | 50,602.15 | 36,913.24 |
| Non-current liabilities | 5,429.24 | 5,338.22 |
| Current Liabilities | 20,920.31 | 20,031.61 |
| Total Equities and Liabilities | 77,199.50 | 62,525.81 |
Total Assets increased to Rs77,199.50 million as of March 31, 2026, compared to Rs62,525.61 million in the previous year. The growth was primarily driven by continued investments in manufacturing capacity expansion, peptide/CDMO capabilities, digital infrastructure and working capital to support business growth across regulated markets. The increase also reflects the Companys continued focus on strengthening its formulations business, enhancing operational capabilities and supporting future growth initiatives.
Equity and Liabilities
Total equity increased from Rs37,155.78 million as of March 31, 2025, to Rs50,849.95 million as of March 31, 2026, primarily driven by profit generated during FY 2025-26, additional equity and application money received against share warrants during the year. The strengthened equity base supported the Companys balance sheet position while enabling continued investments in growth initiatives, manufacturing expansion and strategic business platforms.
Debt Position
(Rs in million)
| Particulars | As on March 31, 2026 | As on March 31, 2025 | Change |
| Long-Term Debt (Current portion) | 156.40 | 517.14 | (360.74) |
| Long-Term Debt (non-current portion) | 2,971.51 | 3,115.11 | (143.60) |
| Short-Term Borrowings | 10,253.42 | 9,225.61 | 1,027.81 |
| Total Debt | 13,381.33 | 12,857.86 | 523.47 |
Cash Flow
(Rs in million)
| Particulars | For the year ended March 31, 2026 | For the year ended March 31, 2025 |
| Opening Cash and Cash equivalents | 4,661.14 | 3,811.00 |
| Cash Flow from Operating Activities | 7,932.50 | 8,665.66 |
| Cash Flow from Investing Activities | (7,732.11) | (6,912.86) |
| Cash Flow from Financing Activities | 3,792.87 | (925.06) |
| Effect of Exchange Rate Changes | 123.93 | 22.40 |
| Cash and cash equivalents pursuant to business combination | 24.05 | - |
| Closing Cash and Cash Equivalents | 8,802.38 | 4,661.14 |
Cash Flow from Operations
Cash flow from operations for FY 2025-26 stood at Rs7,932.50 million compared to Rs8,665.66 million in FY 202425. The Company continued to generate healthy operating cash flows during the year, supported by improved profitability, operational efficiencies and favourable product mix despite higher working capital requirements and investments in growth initiatives.
Capital Expenditures (Capex)
Capital expenditure during FY 2025-26 remained focused on strengthening manufacturing infrastructure, expanding formulation capacities and enhancing peptide/CDMO capabilities. Investments were directed towards the Genome Valley facility, digital and quality infrastructures and strategic growth initiatives including the integration and expansion of Senn Chemicals AG under the Ascelis platform.
Financial Ratios
| Particulars | As on March 31, 2026 | As on March 31, 2025 | % Variance | Reason for Variance (if more than 25%) |
| Debtors Turnover | 5.80 | 4.65 | 25% | - |
| Inventory Turnover | 3.56 | 3.39 | 5% | - |
| Interest Coverage Ratio | 7.95 | 7.10 | 12% | - |
| Current Ratio | 1.80 | 1.56 | 15% | - |
| Debt Equity Ratio | 0.26 | 0.35 | (25%) | - |
| EBITDA Operating Profit Margin (%) | 22.1% | 21.1% | 5% | - |
| Net Profit Margin (%) | 11.1% | 11.2% | (1%) | - |
| Return on Net Worth (%) | 12.2% | 14.4% | (15%) | - |
Internal Control Systems and Adequacy
Given its scale and operational activities, the Company has established and maintains appropriate internal control systems and procedures that encompass all financial and operational aspects. The Company believes that a robust internal control framework is a fundamental element of good corporate governance. It continuously works to improve the systems ability to prevent unauthorised use or losses. The Audit Committee plays a supervisory role over all internal operational matters and provides guidance on necessary corrective measures.
Cautionary Statements
Certain statements in the Management Discussion and Analysis describing the Companys objectives and predictions may constitute forward-looking statements within the meaning of applicable laws and regulations. Actual results may vary significantly from the forward-looking statements in this document due to various risks and uncertainties, including the effects of economic and political conditions in India.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.